Sandoz, Polpharma Overcome US Injunction Bid On Tysabri Biosimilar
Biosimilar Sponsors Remain In Patent Litigation Proceedings, But Court Refuses Block
Sandoz and Polpharma’s September 2022 lawsuit over their proposed biosimilar to Biogen’s Tysabri (natalizumab) has moved a step forward in their favor, after a US court denied the originator’s bid to block a pathway to market for their proposed monoclonal antibody while proceedings continue.
